Sabby Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Sabby Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15,000	Closed	-$52K	–	199
2021 Q1	$52K	Sell	15,000 -50,000	-77%	-$203K	0.01%	154
2020 Q4	$218K	Sell	65,000 -14,470	-18%	-$51.8K	0.04%	83
2020 Q3	$279K	Buy	79,470 +2,500	+3%	+$10.1K	0.04%	95
2020 Q2	$354K	Sell	76,970 -30,607	-28%	-$136K	0.07%	66
2020 Q1	$356K	Buy	107,577 +13,226	+14%	+$60.5K	0.15%	45
2019 Q4	$576K	Sell	94,351 -30,437	-24%	-$125K	0.16%	31
2019 Q3	$520K	Buy	124,788 +41,857	+50%	+$334K	0.28%	36
2019 Q2	$1.09M	Buy	+82,931	New	+$1.02M	1.37%	17

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Sabby Management's PHAS Position: Q2 2021 in Review

Sabby Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 15,000 shares — an estimated $52K sold.

Sabby Management first reported a position in PHAS in Q2 2019 and held it in 8 quarters. The position peaked at $1.09M in Q2 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

Sabby Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Sabby Management sold 15,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $52K.
Sabby Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
Sabby Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.09M in Q2 2019.
55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.